3 ms·
For context, this study was in 2022, this drug had received accelerated approval in 2021 and was fully approved by the FDA in 2023 for mismatch repair deficient
by vikramkr 3y ago
For context, this study was in 2022, this drug had received accelerated approval in 2021 and was fully approved by the FDA in 2023 for mismatch repair deficient endometrial cancer. (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-dostarlimab-gxly-dmmr-endometrial-cancer https://www.fda.gov/drugs/resources-information-approved-dru...).
It's awesome to see the amount of progress in cancer that deeper understanding of the disease is bringing. Identifying interventions that work in a subset of patients with specific mutations, targeting them specifically, using immunotherapies, all incredibly cool and impactful.
- ip26 3y agoSuccess with targeted therapy also hopefully paves the way towards the understanding we need for generalized solutions.
- tomaskafka 3y agoI don't think so - there is no 'general cancer', there's a lot of cancers ...
- vikramkr 3y agoThe better way of thinking about it is that this progress is allowing us to shift away from the idea of 'general' cancer or identifying cancer by tissue of origin to instead start identifying it by more useful and actionable features. So instead of talking about pancreatic cancer or colon cancer, with PD-1 inhibitors like keytruda we instead have an approval for any solid tumor that's mismatch repair deficient, something we can test for and that relates to the efficacy of a specific drug.